KR20100117148A - 폐 질환의 치료 방법 - Google Patents

폐 질환의 치료 방법 Download PDF

Info

Publication number
KR20100117148A
KR20100117148A KR1020107022448A KR20107022448A KR20100117148A KR 20100117148 A KR20100117148 A KR 20100117148A KR 1020107022448 A KR1020107022448 A KR 1020107022448A KR 20107022448 A KR20107022448 A KR 20107022448A KR 20100117148 A KR20100117148 A KR 20100117148A
Authority
KR
South Korea
Prior art keywords
composition
atiii
antithrombin iii
administered
lung injury
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020107022448A
Other languages
English (en)
Korean (ko)
Inventor
가즈노리 무라카미
페렌레이 엔크바타르
릴리언 디 트래버
도널드 에스 프로우
데이빗 엔 헌든
다니엘 엘 트래버
Original Assignee
지티씨바이오쎄라퓨틱스,인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 지티씨바이오쎄라퓨틱스,인크. filed Critical 지티씨바이오쎄라퓨틱스,인크.
Publication of KR20100117148A publication Critical patent/KR20100117148A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020107022448A 2002-04-01 2003-03-25 폐 질환의 치료 방법 Ceased KR20100117148A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36899702P 2002-04-01 2002-04-01
US60/368,997 2002-04-01

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR10-2004-7015636A Division KR20040105838A (ko) 2002-04-01 2003-03-25 폐 질환의 치료 방법

Publications (1)

Publication Number Publication Date
KR20100117148A true KR20100117148A (ko) 2010-11-02

Family

ID=29420316

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020107022448A Ceased KR20100117148A (ko) 2002-04-01 2003-03-25 폐 질환의 치료 방법
KR10-2004-7015636A Ceased KR20040105838A (ko) 2002-04-01 2003-03-25 폐 질환의 치료 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR10-2004-7015636A Ceased KR20040105838A (ko) 2002-04-01 2003-03-25 폐 질환의 치료 방법

Country Status (10)

Country Link
US (1) US20090221475A9 (enExample)
EP (1) EP1494696A4 (enExample)
JP (2) JP2005527570A (enExample)
KR (2) KR20100117148A (enExample)
CN (1) CN100384469C (enExample)
AU (3) AU2003233428B2 (enExample)
CA (1) CA2480790A1 (enExample)
IL (2) IL164078A0 (enExample)
NZ (1) NZ535487A (enExample)
WO (1) WO2003084476A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050169908A1 (en) * 2004-01-23 2005-08-04 Kazunori Murakami Use of aerosolized antithrombin to treat acute lung injury
US20050192226A1 (en) * 2004-02-20 2005-09-01 Perenlei Enkhbaatar Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants
US20050245444A1 (en) * 2004-04-30 2005-11-03 Yann Echelard Method of using recombinant human antithrombin for neurocognitive disorders
US20060121004A1 (en) * 2004-12-07 2006-06-08 Yann Echelard Methods of reducing the incidence of rejection in tissue transplantation through the use of recombinant human antithrombin
US8753882B2 (en) 2010-10-12 2014-06-17 Vetgel Technologies Methods and compositions for treating respiratory conditions using platelet enriched plasma
WO2012090067A1 (en) 2010-12-30 2012-07-05 Lfb Biotechnologies Glycols as pathogen inactivating agents
WO2014140927A2 (en) 2013-02-13 2014-09-18 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Proteins with modified glycosylation and methods of production thereof
EP3594230A1 (en) 2013-02-13 2020-01-15 Laboratoire Français du Fractionnement et des Biotechnologies Highly galactosylated anti-tnf-alpha antibodies and uses thereof
ES2793176T3 (es) 2013-07-05 2020-11-13 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Sa Matriz de cromografía de afinidad
CN106536056B (zh) 2014-06-13 2021-07-16 儿童医学中心公司 分离线粒体的产品和方法
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
EP4653048A2 (en) 2016-01-15 2025-11-26 The Children's Medical Center Corporation Therapeutic use of mitochondria and combined mitochondrial agents
CN113905724A (zh) * 2019-04-15 2022-01-07 儿童医学中心公司 包含线粒体的雾化组合物及其使用方法
WO2022177724A1 (en) * 2021-02-17 2022-08-25 University Of Rochester Methods of treating, diagnosing and predicting prognosis of sepsis

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08782B2 (ja) * 1986-11-22 1996-01-10 株式会社ミドリ十字 抗炎症剤
DE4117078A1 (de) * 1991-05-25 1992-11-26 Boehringer Ingelheim Kg Verfahren zur herstellung therapeutisch anwendbarer aerosole
JPH06256213A (ja) * 1993-03-03 1994-09-13 Green Cross Corp:The ヒト由来アンチトロンビン−ｉｉｉの医薬用途
US6127347A (en) * 1994-01-12 2000-10-03 Univ Michigan Non-anticoagulant chemically modified heparinoids for treating hypovolemic shock and related shock syndromes
US6355626B1 (en) * 1994-05-13 2002-03-12 The Trustees Of The University Of Pennsylvania Antithrombin agents in treatment of asthma
US5843705A (en) * 1995-02-21 1998-12-01 Genzyme Transgenic Corporation Transgenically produced antithrombin III
US6562781B1 (en) * 1995-11-30 2003-05-13 Hamilton Civic Hospitals Research Development Inc. Glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
US7045585B2 (en) * 1995-11-30 2006-05-16 Hamilton Civic Hospital Research Development Inc. Methods of coating a device using anti-thrombin heparin
JPH09176040A (ja) * 1995-12-27 1997-07-08 Green Cross Corp:The ヘパリンコファクターｉｉの医薬用途
US6063593A (en) * 1996-11-12 2000-05-16 University Of Southern California University Park Campus TGFβ1 responsive bone marrow derived cells to express a recombinant protein
US6124257A (en) * 1997-08-28 2000-09-26 Lezdey; John Method of treatment
DE69939179D1 (de) * 1998-10-20 2008-09-04 Childrens Hosp Medical Center Surfactant protein d zur vorbeugung und diagnose des lungenemphysems
US6838428B2 (en) * 1998-10-20 2005-01-04 Children's Hospital Medical Center Surfactant protein D for the prevention and diagnosis of pulmonary emphysema
DE10045047A1 (de) * 2000-09-12 2002-03-21 Beate Kehrel Arzneimittel enthaltend aktiviertes Antithrombin III
AU2440802A (en) * 2000-10-18 2002-04-29 Massachusetts Inst Technology Methods and products related to pulmonary delivery of polysaccharides
DE10132307A1 (de) * 2001-07-06 2003-01-30 Aventis Behring Gmbh Arzneizubereitung zur Inhalation von Antithrombin bei entzündlichen Lungenerkrankungen und ARDS
US20050169908A1 (en) * 2004-01-23 2005-08-04 Kazunori Murakami Use of aerosolized antithrombin to treat acute lung injury
US20050192226A1 (en) * 2004-02-20 2005-09-01 Perenlei Enkhbaatar Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants

Also Published As

Publication number Publication date
KR20040105838A (ko) 2004-12-16
CN100384469C (zh) 2008-04-30
NZ535487A (en) 2008-12-24
US20090221475A9 (en) 2009-09-03
AU2008243077A1 (en) 2008-11-27
US20040192595A1 (en) 2004-09-30
EP1494696A4 (en) 2006-01-25
CA2480790A1 (en) 2003-10-16
WO2003084476A3 (en) 2004-04-22
AU2003233428A1 (en) 2003-10-20
EP1494696A2 (en) 2005-01-12
JP2005527570A (ja) 2005-09-15
WO2003084476A2 (en) 2003-10-16
JP2011225625A (ja) 2011-11-10
AU2003233428B2 (en) 2008-07-31
CN1774258A (zh) 2006-05-17
AU2011236070A1 (en) 2011-11-03
IL164078A0 (en) 2005-12-18
IL164078A (en) 2011-02-28

Similar Documents

Publication Publication Date Title
AU2011236070A1 (en) Treatment of lung disorder
AU2007213344B2 (en) Pulmonary delivery of alpha-I proteinase inhibitor
US5723439A (en) Pharmaceutical aerosol composition and application thereof for treatment and prophylaxis of viral diseases
JPH03501852A (ja) エアゾール化したポリエンを用いる肺の真菌感染の予防及び治療方法
US20220023379A1 (en) Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereof
Hashimoto et al. Aerosolization of imipenem/cilastatin prevents pseudomonas-induced acute lung injury
HK1087930A (en) Treatment of lung disorder
US20040157772A1 (en) Use of a gatran for the manufacture of a medicament of the treatment of pulmonary fibrosis
RS66259B1 (sr) Primena dalargina za prevenciju virusnih respiratornih infekcija i prevenciju razvoja komplikacija tokom virusnih respiratornih infekcija

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20101007

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20101105

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20110120

Patent event code: PE09021S01D

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20110322

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20110928

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20110120

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

A107 Divisional application of patent
J201 Request for trial against refusal decision
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20111229

PJ0201 Trial against decision of rejection

Patent event date: 20111229

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20110928

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20130215

Appeal identifier: 2011101010551

Request date: 20111229

J301 Trial decision

Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20111229

Effective date: 20130215

Free format text: TRIAL NUMBER: 2011101010551; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20111229

Effective date: 20130215

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20130215

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20111229

Decision date: 20130215

Appeal identifier: 2011101010551